Impact of violacein from Chromobacterium violaceum on the mammalian gut microbiome.

Autor: Pauer H; Laboratório de Biologia de Anaeróbios, Departamento de Microbiologia Médica, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.; Escola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil., Hardoim CCP; Laboratório de Interação Hospedeiro-Microbiota, Instituto de Biociências, Universidade Estadual Paulista, Campus do Litoral Paulista, São Vicente, SP, Brazil., Teixeira FL; Laboratório de Biologia de Anaeróbios, Departamento de Microbiologia Médica, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil., Miranda KR; Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Campus Macaé, Macaé, RJ, Brazil., Barbirato DDS; Faculdades Integradas Aparício Carvalho, Porto Velho, RO, Brazil., de Carvalho DP; Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro-Rio de Janeiro, Brazil., Antunes LCM; Escola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.; Instituto Nacional de Ciência e Tecnologia em Inovação em Doenças de Populações Negligenciadas, Centro de Desenvolvimento Tecnológico em Saúde, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil., Leitão ÁADC; Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro-Rio de Janeiro, Brazil., Lobo LA; Laboratório de Biologia de Anaeróbios, Departamento de Microbiologia Médica, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil., Domingues RMCP; Laboratório de Biologia de Anaeróbios, Departamento de Microbiologia Médica, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2018 Sep 13; Vol. 13 (9), pp. e0203748. Date of Electronic Publication: 2018 Sep 13 (Print Publication: 2018).
DOI: 10.1371/journal.pone.0203748
Abstrakt: Violacein is a violet pigment produced by Chromobacterium violaceum that possesses several functions such as antibacterial, antiviral, antifungal, and antioxidant activities. The search for potential compounds and therapies that may interfere with and modulate the gut microbial consortia without causing severe damage and increased resistance is important for the treatment of inflammatory, allergic, and metabolic diseases. The aim of the present work was to evaluate the ability of violacein to change microbial patterns in the mammalian gut by favoring certain groups over the others in order to be used as a therapy for diseases associated with changes in the intestinal microflora. To do this, we used male Wistar rats, and administered violacein orally, in low (50 μg/ml) and high (500 μg/ml) doses for a month. Initially, the changes in the microbial diversity were observed by DGGE analyses that showed that the violacein significantly affects the gut microbiota of the rats. Pyrosequencing of 16S rDNA was then employed using a 454 GS Titanium platform, and the results demonstrated that higher taxonomic richness was observed with the low violacein treatment group, followed by the control group and high violacein treatment group. Modulation of the microbiota at the class level was observed in the low violacein dose, where Bacilli and Clostridia (Firmicutes) were found as dominant. For the high violacein dose, Bacilli followed by Clostridia and Actinobacteria were present as the major components. Further analyses are crucial for a better understanding of how violacein affects the gut microbiome and whether this change would be beneficial to the host, providing a framework for the development of alternative treatment strategies for intestinal diseases using this compound.
Competing Interests: The authors have declared that no competing interests exist.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje